Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Price and Financial Metrics
JAZZ Price/Volume Stats
| Current price | $109.94 | 52-week high | $146.70 |
| Prev. close | $109.27 | 52-week low | $106.61 |
| Day low | $108.88 | Volume | 756,900 |
| Day high | $111.35 | Avg. volume | 615,334 |
| 50-day MA | $119.79 | Dividend yield | N/A |
| 200-day MA | $125.89 | Market Cap | 6.93B |
JAZZ Stock Price Chart Interactive Chart >
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Company Bio
Jazz Pharmaceuticals is an international biopharmaceutical company with a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. The company was founded in 2003 and is based in Dublin, Ireland.
Latest JAZZ News From Around the Web
Below are the latest news stories about JAZZ PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate JAZZ as an investment opportunity.
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot WorldWith the Federal Reserve previously engaged in a bitter – and seemingly, at times desperate – struggle against blisteringly hot inflation, the narrative for growth stocks to buy now frankly didn’t resonate very well with many investors. |
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study GoalsAfter a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug. |
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage StudyJazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in PTSD symptom severity as measured by the Clinician-Administered PTSD Scale between JZP150 (4mg or 0.3mg) compared to placebo from base |
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress DisorderJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS-5) between JZP150 ( |
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update on Monday, January 8, 2024, at 2:15 p.m. PST / 10:15 p.m. GMT. |
JAZZ Price Returns
| 1-mo | -11.41% |
| 3-mo | -5.66% |
| 6-mo | -14.50% |
| 1-year | -24.36% |
| 3-year | -35.25% |
| 5-year | -12.73% |
| YTD | -10.62% |
| 2023 | -22.79% |
| 2022 | 25.05% |
| 2021 | -22.81% |
| 2020 | 10.56% |
| 2019 | 20.43% |
Continue Researching JAZZ
Here are a few links from around the web to help you further your research on Jazz Pharmaceuticals plc's stock as an investment opportunity:Jazz Pharmaceuticals plc (JAZZ) Stock Price | Nasdaq
Jazz Pharmaceuticals plc (JAZZ) Stock Quote, History and News - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...